“A recent retrospective study of an inception cohort of 403,337 patients newly diagnosed with rheumatoid arthritis, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, lupus, and sarcoidosis found 72% to be prescribed glucocorticoids (52% at age <50 years).28 Use of glucocorticoids was strongly associated with increased rate of fractures, “
So Mispec: People don’t yet realise that ATL1102 will replace steroids to treat inflammation ...
The above paragraph shows the indications ATL1102 could treat...
Thats why $2 is very possible (Inflammation market in excess of $120 billion)
- Forums
- ASX - By Stock
- How does ATL1102 compare with Vamorolone
“A recent retrospective study of an inception cohort of 403,337...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.7¢ |
Change
0.002(2.35%) |
Mkt cap ! $78.43M |
Open | High | Low | Value | Volume |
8.6¢ | 8.9¢ | 8.5¢ | $53.40K | 614.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49999 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.9¢ | 67263 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49999 | 0.087 |
2 | 500872 | 0.085 |
2 | 262571 | 0.084 |
1 | 10000 | 0.083 |
2 | 120000 | 0.082 |
Price($) | Vol. | No. |
---|---|---|
0.089 | 67263 | 1 |
0.090 | 546175 | 2 |
0.091 | 108000 | 1 |
0.092 | 135429 | 2 |
0.093 | 175642 | 3 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online